Selected article for: "affected people and disease spread"
Author: Vellas, Camille; Delobel, P.; De Souto Barreto, P.; Izopet, J.
Title: COVID-19, Virology and Geroscience: A Perspective
  • Cord-id: 0pi8qur0
  • Document date: 2020_6_18
    • ID: 0pi8qur0
    Snippet: A new Coronavirus, called SARS-CoV-2, was identified in Wuhan, China, in December 2019. The SARS-CoV-2 spread very rapidly, causing a global pandemic, Coronavirus Disease 2019 (COVID-19). Older adults have higher peak of viral load and, especially those with comorbidities, had higher COVID-19-related fatality rates than younger adults. In this Perspective paper, we summarize current knowledge about SARS-CoV-2 and aging, in order to understand why older people are more affected by COVID-19. We di
    Document: A new Coronavirus, called SARS-CoV-2, was identified in Wuhan, China, in December 2019. The SARS-CoV-2 spread very rapidly, causing a global pandemic, Coronavirus Disease 2019 (COVID-19). Older adults have higher peak of viral load and, especially those with comorbidities, had higher COVID-19-related fatality rates than younger adults. In this Perspective paper, we summarize current knowledge about SARS-CoV-2 and aging, in order to understand why older people are more affected by COVID-19. We discuss about the possibility that the so-called “immunosenescence” and “inflammaging” processes, already present in a fraction of frail older adults, could allow the immune escape of SARS-CoV-2 leading to COVID-19 serious complications. Finally, we propose to use geroscience approaches to the field of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and adaptive immune system: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and adaptive innate immunity: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and adequately control: 1, 2
    • acute ards respiratory distress syndrome and long term effect: 1
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and low grade inflammation: 1, 2
    • acute ards respiratory distress syndrome and lung epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and lung increase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute ards respiratory distress syndrome and lymphoid tissue: 1, 2, 3, 4
    • acute cytokine storm and adaptive immune response: 1, 2, 3
    • acute cytokine storm and adaptive immune system: 1, 2, 3
    • acute cytokine storm and adaptive innate: 1, 2, 3, 4, 5, 6, 7
    • acute cytokine storm and adaptive innate immunity: 1
    • acute cytokine storm and lopinavir ritonavir: 1, 2
    • acute cytokine storm and low grade inflammation: 1
    • acute cytokine storm and lung epithelial cell: 1, 2
    • adaptive immune function and low grade inflammation: 1, 2